Skip to main content
. Author manuscript; available in PMC: 2021 Oct 7.
Published in final edited form as: Kidney Cancer. 2021 Aug 28;5(3):115–127. doi: 10.3233/KCA-210119

Table 4:

Unadjusted and Multivariable-Adjusted Relative Cost Ratios for OAA Use and Race Associations for Total Medicare Costs, Total Cancer-specific Medicare Costs, and Total Inpatient Admission-specific Medicare Costs in the 12 Months Following a Patient’s Metastatic RCC Diagnosis

Parameter Unadjusted Relative Cost Ratios
RCR (95% CI)
Multivariable-adjusted Relative Cost Ratiosa
RCR (95% CI)
Total Costs in 12 months post-dx
OAA Use (ref. none) 1.40 (1.31-1.49) 1.36 (1.28-1.45)
Race (ref. White Non-Hispanic)
 Black Non-Hispanic 0.86 (0.76-0.97) 1.00 (0.88-1.14)
 Hispanic 1.08 (0.98-1.20) 1.19 (1.06-1.33)
 Other 0.99 (0.88-1.12) 1.04 (0.92-1.18)
Cancer-specific Costs in 12 months post-dx
OAA Use (ref. none) 1.48 (1.35-1.62) 1.47 (1.34-1.61)
Race (ref. White Non-Hispanic)
 Black Non-Hispanic 0.68 (0.57-0.81) 0.92 (0.76-1.11)
 Hispanic 1.01 (0.88-1.17) 1.20 (1.01-1.41)
 Other 0.96 (0.80-1.14) 1.02 (0.85-1.22)
Inpatient Admission Costs in 12 months post-dx
OAA Use (ref. none) 1.13 (1.06-1.22) 1.08 (1.01-1.16)
Race (ref. White Non-Hispanic)
 Black Non-Hispanic 1.06 (0.93-1.20) 1.07 (0.93-1.23)
 Hispanic 1.25 (1.13-1.40) 1.09 (0.97-1.23)
 Other 1.25 (1.09-1.42) 1.08 (0.94-1.24)
a

Multivariable models additionally adjusted for patient age, sex, cancer stage at initial diagnosis, tumor histology, region of residence, residence in metropolitan area, year of metastatic diagnosis, Medicaid dual enrollment status, zip code characteristics, patient comorbidities, and patient’s prior year total Medicare spending